You've heard of Ozempic. You probably know about Mounjaro. If you read our coverage, you're aware of CagriSema — the combination shot pairing semaglutide with an amylin analog. But what if you could take the dual-hormone concept behind CagriSema and engineer it into a single molecule? One that works as both a shot and a pill?
That's amycretin. And the early data is raising eyebrows across the obesity research world.
Developed by Novo Nordisk — the same company behind Ozempic, Wegovy, and CagriSema — amycretin is a first-in-class unimolecular GLP-1 and amylin receptor agonist. In plain English: it's one engineered peptide that simultaneously activates two different appetite-suppressing hormone pathways. Phase 1b/2a data showed up to 22% weight loss in 36 weeks. Phase 3 trials are launching in 2026 for both obesity and type 2 diabetes. And unlike most injectable peptide therapies, amycretin is being developed in oral form as well.
Here's what makes it worth paying attention to — and what the clinical data actually tells us.
The Two-Hormone Problem That Amycretin Solves
To understand why amycretin matters, you need to understand why one hormone isn't enough for some patients.
GLP-1: The Hormone Everyone Knows
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) have dominated the weight loss conversation for the past three years. They work primarily through the hypothalamus, suppressing homeostatic hunger — the biological "I need calories" signal. They also slow gastric emptying, enhance insulin secretion, and suppress glucagon release.
The results have been transformative. Semaglutide produces roughly 15% weight loss. Tirzepatide (which adds GIP receptor activity) pushes that to 20-22%. But there's a ceiling, and not every patient responds equally. Some people plateau early. Others experience dose-limiting nausea before reaching therapeutic levels. And a subset of patients — perhaps 10-15% — are relative non-responders to GLP-1-based therapies.
Amylin: The Hormone That Got Overlooked
Amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells after every meal. Discovered in 1987, it spent decades overshadowed by insulin and GLP-1. But amylin has a distinct and complementary set of biological effects:
- Promotes satiety through the area postrema and nucleus of the solitary tract in the brainstem
- Slows gastric emptying through mechanisms distinct from GLP-1
- Suppresses glucagon after meals, preventing blood sugar spikes
- Increases energy expenditure via central nervous system pathways
- Reduces hedonic eating by acting on reward-related brain circuits
The key distinction: while GLP-1 primarily targets the hypothalamus and homeostatic hunger, amylin works through the hindbrain and targets both homeostatic and hedonic appetite — the "that food looks amazing" signal that makes you reach for dessert after a full meal.
| Feature | GLP-1 Pathway | Amylin Pathway |
|---|---|---|
| Primary brain target | Hypothalamus | Hindbrain (area postrema) |
| Hunger type suppressed | Homeostatic ("need calories") | Homeostatic + hedonic ("want food") |
| Gastric emptying | Slows | Slows (different mechanism) |
| Glucagon suppression | Glucose-dependent | Post-meal |
| Receptor type | GLP-1R | AMY1, AMY3, CTR |
| Energy expenditure | Modest increase | Increases via CNS |
The logic is straightforward: if you can hit both pathways simultaneously, you should get better appetite suppression than either alone. CagriSema proved this concept by combining two separate molecules (semaglutide + cagrilintide) in one injection. But there's an engineering elegance to doing it with a single molecule.
What Makes Amycretin Different: One Molecule, Two Receptors
Amycretin isn't a mixture of two drugs. It's a single engineered peptide that contains both a GLP-1 receptor agonist moiety and an amylin receptor agonist moiety, connected by a short linker made of four glycine residues and one glutamate residue.
This matters for several practical reasons:
Simplified manufacturing. Producing one molecule is less complex than producing and combining two. That should eventually translate to lower costs and fewer supply chain constraints — a real issue in a market where semaglutide shortages have been a persistent problem.
Oral formulation potential. This is the big one. CagriSema is an injection — combining two peptides into a stable oral form would be extremely challenging. A single molecule is more amenable to oral delivery engineering. Novo Nordisk is already developing oral amycretin, and early clinical data shows it works.
Consistent pharmacokinetics. With a combination like CagriSema, the two components may have slightly different absorption rates, distribution patterns, and clearance timelines. A unimolecular agonist eliminates these pharmacokinetic mismatches — both activities rise and fall together.
Flexible dosing. Because the GLP-1 and amylin activities are locked in a fixed ratio within the molecule, there's no need to independently titrate two components. One dose, one ratio, one schedule.
Preclinical Foundation
Before entering human trials, amycretin was tested extensively in mouse and rat models of obesity and metabolic dysfunction. Published data in eBioMedicine showed that amycretin reduced body weight, improved glucose tolerance, and decreased liver fat more effectively than GLP-1 agonism alone. Importantly, the preclinical work suggested that the amylin component contributed additional effects beyond what GLP-1 provides — particularly in reducing hedonic food intake and improving hepatic lipid metabolism.
The Clinical Data: What We Actually Know
Phase 1: First-in-Human (Oral Formulation)
The first clinical study of amycretin tested the oral formulation in people with overweight or obesity. The results, presented in The Lancet, were striking for an oral peptide:
- 13.1% body weight reduction after just 12 weeks of treatment
- Adverse events were primarily gastrointestinal (nausea, vomiting) and mostly mild to moderate
- No serious safety signals
For context, oral semaglutide (Rybelsus) produces roughly 3-4% weight loss over a similar timeframe at therapeutic doses. An oral peptide achieving 13% in 12 weeks immediately signaled that this was not a marginal improvement.
Phase 1b/2a: Subcutaneous Formulation (Obesity)
The pivotal early-stage trial tested subcutaneous amycretin at three dose levels in adults with obesity or overweight, published in The Lancet in 2025:
| Dose | Duration | Estimated Weight Loss | Placebo-Corrected |
|---|---|---|---|
| 1.25 mg/week | 20 weeks | 9.7% | ~8.5% |
| 5 mg/week | 28 weeks | 16.2% | ~15.0% |
| 20 mg/week | 36 weeks | 22.0% | ~20.8% |
The 22% weight loss at the highest dose is comparable to what tirzepatide achieved in the SURMOUNT trials — but amycretin reached these numbers faster and in a smaller, earlier-stage trial. The weight loss trajectory was still accelerating at study end, suggesting the maximum effect hadn't been reached.
Safety profile: The most common side effects were nausea (40-60% across dose groups), vomiting (20-35%), and decreased appetite. The vast majority were mild to moderate and concentrated during the dose-escalation phase. No pancreatitis cases were reported, and no participants withdrew due to safety concerns at the highest dose.
Phase 2: Type 2 Diabetes
In November 2025, Novo Nordisk reported results from a Phase 2 trial in people with type 2 diabetes, testing both subcutaneous and oral formulations:
Subcutaneous amycretin (once weekly):
- HbA1c reduction: up to 1.8% from a baseline of 7.8%
- Weight loss: up to 14.5% (vs. 2.6% placebo)
- 89.1% of patients reached HbA1c below 7%
Oral amycretin (once daily):
- HbA1c reduction: up to 1.5% from a baseline of 8.0%
- Weight loss: up to 10.1% from a mean baseline of 101.1 kg (vs. 2.5% placebo)
Both formulations demonstrated a safe and well-tolerated profile. The fact that oral amycretin delivered meaningful weight loss and glucose control in a diabetic population — where weight loss is typically harder — is clinically significant.
How Does Amycretin Compare?
The metabolic peptide landscape in 2026 is crowded with next-generation candidates. Here's where amycretin fits:
| Drug | Mechanism | Peak Weight Loss | Route | Stage |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | ~15-17% | SC injection, oral | Approved |
| Tirzepatide (Zepbound) | GLP-1 + GIP | ~22-25% | SC injection | Approved |
| CagriSema | GLP-1 + Amylin (two molecules) | ~22-25% | SC injection | NDA filed |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24-26% | SC injection | Phase 3 |
| Orforglipron | GLP-1 (small molecule) | ~14-15% | Oral | Phase 3 |
| Amycretin | GLP-1 + Amylin (one molecule) | ~22% | SC injection + oral | Phase 3 (2026) |
| Survodutide | GLP-1 + Glucagon | ~18-20% | SC injection | Phase 3 |
| Pemvidutide | GLP-1 + Glucagon | ~7.5% (MASH focus) | SC injection | Phase 3 (2026) |
Amycretin vs. CagriSema: The Sibling Rivalry
This is the most natural comparison because both target GLP-1 and amylin pathways. They come from the same company, hit the same receptors, and aim at the same patients. The differences are structural and practical:
CagriSema combines two separate molecules — semaglutide and cagrilintide — in a single injection. It has more extensive clinical data (Phase 3 REDEFINE trials with ~22.7% weight loss), an NDA already filed with the FDA, and a likely approval timeline in late 2026.
Amycretin packs both activities into one molecule. It's earlier in development but offers the potential for oral delivery, simpler manufacturing, and potentially lower long-term costs. Novo Nordisk's stated expectation is that amycretin will match CagriSema's efficacy and safety, with added convenience.
The likely scenario: CagriSema reaches the market first as an injectable, and amycretin follows as both an injectable and a pill — giving patients a choice of delivery method for the same dual-pathway approach.
Amycretin vs. Tirzepatide: Different Dual, Different Targets
Tirzepatide targets GLP-1 and GIP receptors, while amycretin targets GLP-1 and amylin receptors. Both achieve roughly similar peak weight loss (~22%), but through different biological mechanisms.
There's a plausible argument that the approaches could be complementary for different patient populations. GIP activity may confer specific metabolic advantages in insulin sensitivity and lipid metabolism, while amylin activity may provide stronger hedonic appetite suppression and additional gastric emptying effects. Until head-to-head trials exist, we won't know which approach works better for which patients.
The Oral Advantage
Here's where amycretin may have its most significant edge. While orforglipron is the leading oral GLP-1 candidate, it's a small molecule — not a peptide — and it only targets GLP-1 receptors. Amycretin would be the first dual-agonist available as an oral formulation. For the millions of patients who resist injectable therapy (needle phobia is real and clinically relevant), an oral dual agonist is a potentially transformative option.
The Phase 1 oral data — 13.1% weight loss in 12 weeks — is remarkable for an oral formulation. The Phase 2 diabetes data confirmed that oral delivery maintains meaningful efficacy. If Phase 3 confirms these results at scale, oral amycretin could become the most effective weight loss pill ever developed.
The Phase 3 Roadmap
Novo Nordisk has laid out an aggressive development timeline:
Obesity Program (Q1 2026 launch):
- Both subcutaneous and oral formulations entering Phase 3
- Regulatory feedback received and end-of-Phase 2 meetings completed
- Expected to enroll thousands of adults with obesity or overweight
- Primary endpoints: percent weight change and proportion of participants achieving clinically meaningful weight loss thresholds
Type 2 Diabetes Program (2026 launch):
- Phase 3 development expanded after positive Phase 2 results
- Will test both subcutaneous and oral formulations
- Co-primary endpoints expected to include HbA1c reduction and weight change
The decision to advance both formulations directly to Phase 3 — without additional Phase 2 dose-ranging — signals high confidence from both Novo Nordisk and regulators. If trials stay on schedule, the earliest possible approval timeline would be 2028-2029.
The Amylin Renaissance: Why Now?
Amycretin isn't developing in a vacuum. It's part of a broader resurgence of interest in amylin-based therapeutics that has several converging drivers:
1. GLP-1 plateau recognition. After years of GLP-1 dominance, researchers are acknowledging that single-pathway approaches have limitations. Approximately 10-15% of patients are relative non-responders to GLP-1 agonists, and even responders eventually hit a weight loss plateau. Adding a second pathway offers a route past that ceiling.
2. The hedonic appetite gap. GLP-1 agonists are excellent at reducing homeostatic hunger, but many patients still struggle with cravings, emotional eating, and reward-driven food behavior. Amylin's action on hindbrain reward circuits addresses this gap specifically.
3. Improved peptide engineering. The failure of pramlintide (Symlin) in the 2000s — an amylin analog that required three daily injections — demonstrated the need for long-acting formulations. Modern peptide engineering techniques, including fatty acid conjugation and molecular stabilization, have solved the half-life problem that killed the first generation.
4. Oral delivery breakthroughs. The SNAC technology behind oral semaglutide (Rybelsus) proved that peptide oral delivery was possible. Amycretin builds on this progress, and Novo Nordisk's experience with oral semaglutide likely informed their oral amycretin development program.
5. Complementary mechanisms validated. CagriSema's Phase 3 data proved that combining GLP-1 and amylin pathways produces clinically superior weight loss compared to either alone. Amycretin is the next iteration of this validated concept.
Questions That Phase 3 Needs to Answer
The early data is promising, but Phase 1 and 2 trials are designed to show signal — not to definitively prove safety and efficacy. Several important questions remain:
Does 22% weight loss hold in larger populations? Phase 1b/2a trials are small (typically 50-150 participants) and carefully controlled. Phase 3 trials enroll thousands of patients with greater demographic and genetic diversity. Weight loss numbers often moderate — not always dramatically, but the Phase 3 result is what matters for approval and clinical practice.
What's the long-term safety profile? Most adverse events in early trials were gastrointestinal and mild to moderate. But 36 weeks of data is not enough to assess long-term risks. Thyroid concerns, pancreatitis risk, potential effects on bone density, and cardiovascular outcomes all need longer observation periods.
How does oral amycretin perform in Phase 3? The 13.1% weight loss at 12 weeks with oral amycretin is exciting, but early oral peptide data can be variable. Absorption is affected by food, gastric pH, intestinal transit time, and patient compliance with dosing instructions. Scaling to thousands of patients in real-world conditions is the real test.
Muscle mass preservation. One of the ongoing criticisms of GLP-1-based weight loss therapies is that a significant portion of weight lost is lean muscle mass — not just fat. Does the amylin component help preserve muscle, or does dual-pathway appetite suppression exacerbate the problem? Preclinical data suggests amylin may have modest muscle-sparing effects, but human data is needed.
What happens when patients stop? Weight regain after discontinuation has been demonstrated with semaglutide and tirzepatide. Will amycretin's dual mechanism alter the regain trajectory, or will the same pattern emerge?
Head-to-head data. There are no direct comparisons between amycretin and CagriSema, tirzepatide, or retatrutide. These trials are essential for determining amycretin's position in the treatment hierarchy but will take years to complete.
What This Means for the Bigger Picture
The metabolic peptide field is moving from a single-hormone paradigm to a multi-hormone one at remarkable speed:
- 2017-2021: GLP-1 single agonists (semaglutide, liraglutide) dominate
- 2022-2024: Dual agonists arrive (tirzepatide: GLP-1/GIP)
- 2025-2026: Amylin combinations enter late-stage development (CagriSema, amycretin)
- 2025-2026: Triple agonists advance (retatrutide: GLP-1/GIP/glucagon)
- 2026+: Oral multi-agonists reach Phase 3 (oral amycretin)
Amycretin represents a specific inflection point: the first attempt to deliver dual-agonist potency in a single molecule that works as a pill. If it succeeds, the implications extend beyond weight loss:
Access. Injectable therapies create barriers — cold chain requirements, needle anxiety, clinical visits for injection training. An effective oral dual agonist could dramatically expand the number of patients willing and able to use these therapies.
Cost. Unimolecular compounds are generally cheaper to produce than multi-drug combinations. In a market where annual costs exceed $10,000-15,000 per patient, manufacturing efficiency matters.
Personalization. As more multi-agonist options become available, clinicians will eventually be able to match patients with the specific receptor combination that works best for their metabolic profile. GLP-1/GIP for some. GLP-1/amylin for others. GLP-1/GIP/glucagon for severe cases. This is the beginning of personalized metabolic medicine.
The Bottom Line
Amycretin is not a sure thing. It's a Phase 2-to-3 transition molecule — the most treacherous stage in drug development, where many promising candidates fail. The weight loss numbers are impressive but come from small, short-duration trials. The oral formulation is compelling but unproven at scale. And the safety profile, while clean so far, needs years of additional data.
But the concept is sound, the preclinical and early clinical data are strong, and the practical advantages of a unimolecular oral dual agonist are real. Novo Nordisk is arguably the most experienced company in the world at developing GLP-1 and amylin-based therapies, and they're betting heavily on amycretin as a successor to their current portfolio.
What we know:
- 22% weight loss with subcutaneous amycretin at 36 weeks (Phase 1b/2a)
- 13.1% weight loss with oral amycretin at 12 weeks (Phase 1)
- Up to 1.8% HbA1c reduction in type 2 diabetes (Phase 2)
- Dual GLP-1/amylin agonism in a single molecule — first in class
- Both oral and injectable forms advancing to Phase 3 in 2026
What we don't know:
- Whether Phase 3 trials will confirm early efficacy signals
- Long-term safety beyond 36 weeks
- How it compares head-to-head against CagriSema, tirzepatide, or retatrutide
- Whether muscle mass loss is better or worse than existing therapies
- Pricing, availability, and insurance coverage
What to watch:
- Phase 3 enrollment and timeline updates (2026)
- Interim data readouts (likely 2027-2028)
- CagriSema FDA decision (late 2026) — which will set the commercial context
- Head-to-head trial designs announced against competitors
- Any new data on oral amycretin durability and real-world adherence
The obesity treatment landscape is evolving faster than anyone predicted five years ago. Amycretin represents the next iteration: same dual-pathway science, better molecular engineering, and the first real shot at putting dual-agonist potency into a pill. Whether it lives up to the promise depends on Phase 3 — but the early chapters of this story are worth reading carefully.
This article is for informational purposes only and does not constitute medical advice. Amycretin is an investigational drug currently in clinical development and is not approved for any indication. Do not attempt to obtain or use amycretin outside of clinical trials. Consult a qualified healthcare provider for personalized medical guidance.